JP2017535547A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535547A5
JP2017535547A5 JP2017525897A JP2017525897A JP2017535547A5 JP 2017535547 A5 JP2017535547 A5 JP 2017535547A5 JP 2017525897 A JP2017525897 A JP 2017525897A JP 2017525897 A JP2017525897 A JP 2017525897A JP 2017535547 A5 JP2017535547 A5 JP 2017535547A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
administration
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017525897A
Other languages
English (en)
Japanese (ja)
Other versions
JP6861630B2 (ja
JP2017535547A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060540 external-priority patent/WO2016077675A1/en
Publication of JP2017535547A publication Critical patent/JP2017535547A/ja
Publication of JP2017535547A5 publication Critical patent/JP2017535547A5/ja
Application granted granted Critical
Publication of JP6861630B2 publication Critical patent/JP6861630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017525897A 2014-11-14 2015-11-13 Il−4rアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法 Active JP6861630B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462080092P 2014-11-14 2014-11-14
US62/080,092 2014-11-14
US201462083821P 2014-11-24 2014-11-24
US62/083,821 2014-11-24
US201562158832P 2015-05-08 2015-05-08
US62/158,832 2015-05-08
US201562199305P 2015-07-31 2015-07-31
US62/199,305 2015-07-31
EP15306632 2015-10-14
EP15306632.9 2015-10-14
PCT/US2015/060540 WO2016077675A1 (en) 2014-11-14 2015-11-13 Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021001858A Division JP7216122B2 (ja) 2014-11-14 2021-01-08 Il-4rアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法

Publications (3)

Publication Number Publication Date
JP2017535547A JP2017535547A (ja) 2017-11-30
JP2017535547A5 true JP2017535547A5 (cg-RX-API-DMAC7.html) 2018-12-20
JP6861630B2 JP6861630B2 (ja) 2021-04-21

Family

ID=54330704

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017525897A Active JP6861630B2 (ja) 2014-11-14 2015-11-13 Il−4rアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
JP2023005585A Pending JP2023052458A (ja) 2014-11-14 2023-01-18 Il-4rアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
JP2025003986A Pending JP2025063155A (ja) 2014-11-14 2025-01-10 Il-4rアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023005585A Pending JP2023052458A (ja) 2014-11-14 2023-01-18 Il-4rアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
JP2025003986A Pending JP2025063155A (ja) 2014-11-14 2025-01-10 Il-4rアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法

Country Status (11)

Country Link
US (3) US10066017B2 (cg-RX-API-DMAC7.html)
EP (1) EP3218412A1 (cg-RX-API-DMAC7.html)
JP (3) JP6861630B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230158131A (cg-RX-API-DMAC7.html)
CN (1) CN107206073A (cg-RX-API-DMAC7.html)
AU (3) AU2015346150B2 (cg-RX-API-DMAC7.html)
CA (2) CA2967602C (cg-RX-API-DMAC7.html)
IL (4) IL303337B1 (cg-RX-API-DMAC7.html)
MX (2) MX2017006286A (cg-RX-API-DMAC7.html)
RU (1) RU2734490C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016077675A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PT3470432T (pt) 2012-08-21 2021-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
BR112015005048A8 (pt) 2012-09-07 2018-01-30 Regeneron Pharma métodos para tratar dermatite atópica por administração de antagonista il-4r
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
JP6526037B2 (ja) 2014-02-28 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−4rアンタゴニストを投与することによる皮膚感染を処置するための方法
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
CA3035202A1 (en) * 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018190990A1 (en) * 2017-04-13 2018-10-18 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology HEALTHY AND SICK BARRIER TISSUE CELL ATLAS
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
CA3079946A1 (en) * 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
RU2667819C1 (ru) * 2017-12-20 2018-09-24 Владимир Викторович Сунцов Способ аэрозольной терапии риносинуситов
WO2019157304A1 (en) * 2018-02-09 2019-08-15 Empirico Inc. Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
JP2021523188A (ja) 2018-05-13 2021-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
US11448651B2 (en) * 2018-07-10 2022-09-20 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-exisiting interactions
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
EP3911632A1 (en) 2019-01-15 2021-11-24 Empirico Inc. Prodrugs of alox-15 inhibitors and methods of using the same
CN121102493A (zh) 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
CA3147436A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
MX2022001247A (es) 2019-08-05 2022-04-25 Regeneron Pharma Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
KR20240038841A (ko) * 2022-09-16 2024-03-26 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이의 용도
CN116819076A (zh) * 2023-05-26 2023-09-29 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗慢性鼻窦炎伴鼻息肉中疗效的生物标志物、应用和方法
EP4623903A1 (en) 2024-03-28 2025-10-01 Fresenius Kabi Deutschland GmbH Pharmaceutical composition comprising dupilumab

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU665763B2 (en) 1991-05-03 1996-01-18 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
EP1113818B1 (en) 1998-09-18 2006-05-17 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP1283851B1 (en) 2000-05-26 2012-03-28 Immunex Corporation Use of il-4r antibodies and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR100572408B1 (ko) 2000-07-26 2006-04-19 가부시키가이샤 호오도 진양성 조성물 및 창상치유촉진 조성물
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1229034B1 (en) 2001-01-31 2005-04-13 Pfizer Products Inc. Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
BR0117009A (pt) 2001-05-11 2004-04-20 Novartis Ag Composiçoes para utilização no tratamento de distúrbios associados a ige
JP4339598B2 (ja) 2001-05-23 2009-10-07 デュオトール アーベー 毒素サブユニットまたはそのフラグメントと共に、又はこれとコンジュゲートされたアレルゲンの経皮投与によるアレルギー反応の抑制
WO2003048083A2 (en) 2001-11-30 2003-06-12 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
CN1326879C (zh) 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
CA2514839A1 (en) 2003-02-01 2004-08-19 Tanox, Inc. A method for generating high affinity antibodies
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
WO2005085284A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2636854A1 (en) 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
EP2091551B1 (en) 2006-11-03 2020-01-15 Alba Therapeutics Corporation Method of treating asthma
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US20090062168A1 (en) 2007-08-27 2009-03-05 Joseph Timar Process for making a two-cycle gasoline engine lubricant
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CA2708871C (en) 2007-12-21 2017-11-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CA2748712A1 (en) 2008-12-01 2010-06-10 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
US20120088814A1 (en) * 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
RU2403071C1 (ru) * 2009-09-03 2010-11-10 Логина Наталия Алексеевна Способ лечения хронических рецидивирующих воспалительных заболеваний слизистой носа и околоносовых пазух методом эндоназальной аутолимфоцитотерапии
CN102596237A (zh) 2009-09-07 2012-07-18 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP2708259A1 (en) 2010-03-16 2014-03-19 Airsonett AB Treatment of asthma, allergic rhinitis and improvement of quality of sleep by temperature controlled laminar airflow treatment
EP2585075B8 (en) 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
PH12013500672A1 (en) 2010-10-06 2013-06-03 Regeneron Pharma Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies
UA111731C2 (uk) 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
WO2012094643A2 (en) 2011-01-06 2012-07-12 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
EP2723899B1 (en) 2011-06-21 2020-11-18 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
EP2763683A1 (en) 2011-10-06 2014-08-13 N.V. Nutricia Treatment of eosinophilic esophagitis
CN104039352A (zh) 2011-11-01 2014-09-10 米迪缪尼有限公司 用于降低哮喘急性恶化的频率和严重性的方法
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
EP2677838B1 (en) 2012-06-18 2017-12-06 Whirlpool Corporation Microwave heating apparatus
PT3470432T (pt) 2012-08-21 2021-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
BR112015005048A8 (pt) 2012-09-07 2018-01-30 Regeneron Pharma métodos para tratar dermatite atópica por administração de antagonista il-4r
WO2014059178A1 (en) 2012-10-10 2014-04-17 Rhode Island Hospital Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
JP6526037B2 (ja) 2014-02-28 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−4rアンタゴニストを投与することによる皮膚感染を処置するための方法
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
IL285483B (en) * 2014-11-14 2022-08-01 Regeneron Pharma Methods for the treatment of chronic sinusitis with nasal polyps by adding an il-4r antagonist
AU2017220184B2 (en) 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
CA3035202A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist

Similar Documents

Publication Publication Date Title
JP2017535547A5 (cg-RX-API-DMAC7.html)
RU2017120437A (ru) Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
JP2023052458A5 (cg-RX-API-DMAC7.html)
JP2016523863A5 (cg-RX-API-DMAC7.html)
Verschueren et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial
RU2016101632A (ru) Способы лечения полипоза носа путем введения антагониста il-4r
JP2019511488A5 (cg-RX-API-DMAC7.html)
JP2021501169A5 (cg-RX-API-DMAC7.html)
JP2017507139A5 (cg-RX-API-DMAC7.html)
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2015527364A5 (cg-RX-API-DMAC7.html)
JP2013521303A5 (cg-RX-API-DMAC7.html)
JP2015505564A5 (cg-RX-API-DMAC7.html)
Reid Osteoporosis treatment: focus on safety
JP2020502261A5 (cg-RX-API-DMAC7.html)
EA032067B1 (ru) Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита
US20090131382A1 (en) Treatment of rheumatoid arthritis using imatinib
JP2016534996A5 (cg-RX-API-DMAC7.html)
JP2025072440A5 (cg-RX-API-DMAC7.html)
JPWO2019222055A5 (cg-RX-API-DMAC7.html)
JP2020073525A5 (cg-RX-API-DMAC7.html)
van Ouwerkerk et al. Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?
JP2018529747A5 (cg-RX-API-DMAC7.html)
TW202515610A (zh) 治療克隆氏症(crohn's disease)的方法
HRP20191709T1 (hr) Postupci liječenja nosne polipoze davanjem antagonista il-4r